Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
Open accessThe DOI matches its Crossref record; 24 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Several combinations of 2 or 3 direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naive patients. DAAs for HCV infection have similar mechanisms of action and chemical structures to antiretrovirals for human immunodeficiency virus (HIV) infection. Generic antiretrovirals are currently manufactured at very low prices, to treat 10 million people with HIV/AIDS in developing countries. METHODS: Four HCV DAAs, currently either in phase 3 development or recent approval (daclatasvir, sofosbuvir, simeprevir, faldaprevir), and ribavirin were classified by chemical structure, molecular weight, total daily dose, and complexity of synthesis. The likely range of manufacturing costs per gram of DAA were then projected as formulated product cost, based upon treating a minimum of 1 million patients annually (to arrive at volume demand) combined with an analysis of the complexity of synthesis and a 40% margin for formulation. Projections were then compared with actual costs of antiretrovirals with similar structures. RESULTS: Minimum manufacturing costs of antiretrovirals were US$0.2-$2.1 per gram. The complexity of chemical synthesis for HCV DAAs was ranked from lowest to highest: ribavirin, daclatasvir, sofosbuvir, faldaprevir, and simeprevir. Predicted manufacturing costs (US dollars) for 12-week courses of HCV DAAs were $21-$63 for ribavirin, $10-$30 for daclatasvir, $68-$136 for sofosbuvir, $100-$210 for faldaprevir, and $130-$270 for simeprevir. CONCLUSIONS: Within the next 15 years, large-scale manufacture of 2 or 3 drug combinations of HCV DAAs is feasible, with minimum target prices of $100-$250 per 12-week treatment course. These low prices could make widespread access to HCV treatment in low- and middle-income countries a realistic goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our methodology for calculating drug EMPs has previously accurately predicted how low medication prices can go when they are produced generically [31]; however, this methodology is based on multiple assumptions.”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with cost-based pricing research similar to this, alongside advocacy groups and political will, treatment courses were brought down to <$100 per 12-week treatment course [31,40].”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“when direct-acting antivirals were developed for hepatitis C 10 years ago, courses were $84,000 per person ($1000/pill)”
From Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment (2023) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515 · cited 1×
“Worldwide, 160–180 million people are antibody positive for Hepatitis C, with up to 500 000 HCV-related deaths per year [1, 2].”
BackgroundEvolving epidemiology of hepatitis C virus
Lavanchy, D. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03432.x · Cited by 1,318 · cited 1×
“Sources: Lavanchy [8]; Negro and Alberti [9].”
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090 · cited 2×
“Sofosbuvir + RBV POSITRON [15] (n = 207 + 71 placebo) IFN-ineligible 2 12 wk (n = 109) 93% (SVR-12)”
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“Daclatasvir has a straightforward synthesis with the cost-limiting intermediate being the substituted biphenyl compound shown (Table 5) [21, 22].”
BackgroundThe WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings
Gilks, C. F., Crowley, S., Ekpini, R., Gove, S., Perriens, J., Souteyrand, Y., Sutherland, D., Vitoria, M., Guerma, T., & De Cock, K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69158-7 · Cited by 689 · cited 1×
“proaches using tolerable, easy-to-administer regimens that are supportive of task shifting (care delivery by lesser trained health staff ) and good patient adherence, and could be facilitated by widespread access to oral, short-course DAA therapy in lowincome countries [29].”
BackgroundWitkowski, J. T., Robins, R. K., Sidwell, R. W., & Simon, L. N. (1972) · Journal of Medicinal Chemistry · doi:10.1021/jm00281a014 · Cited by 471 · cited 1×
“Analysis revealed that ribavirin has a relatively simple chemical synthesis [20].”
BackgroundLow-cost tools for diagnosing and monitoring HIV infection in low-resource settings
Wu, G., & Zaman, M. H. (2012) · Bulletin of the World Health Organization · doi:10.2471/blt.12.102780 · Cited by 190
The global health burden of hepatitis C virus infection
Negro, F., & Alberti, A. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02537.x · Cited by 181 · cited 1×
“Sources: Lavanchy [8]; Negro and Alberti [9].”
Moon, S., Jambert, E., Childs, M., & von Schoen-Angerer, T. (2011) · Globalization and Health · doi:10.1186/1744-8603-7-39 · Cited by 138
Research works printed but not linked: 5
- 2013, Journal of hepatology, 58, S22
- 2012, Clinical Infectious Diseases, 54, 145
- 2012, Hepatology (Baltimore, Md.), 56, 230A
- 2012, Hepatology (Baltimore, Md.), 56, 306A
- 2012, Hepatology (Baltimore, Md.), 56, 308A
Cited by
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19
Khalili, J. S., Zhu, H., Mak, N. S. A., Yan, Y., & Zhu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25798 · Cited by 359
“10 per gram.(29) An example of over‐the‐counter retail ribavirin cost in China is as follows: 1800mg of ribavirin retail price is approximately US $1.”
BackgroundChhatwal, J., Kanwal, F., Roberts, M. S., & Dunn, M. A. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1336 · Cited by 338
“lawmakers (13), the World Health Organization (14), and private payers (15), especially given that its manufacturing cost is $200 for 12-week treatment (16).”
BackgroundIyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K., & Hill, S. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002032 · Cited by 255
“A recent study estimated the cost of production of sofosbuvir to be US$68–US$136 for a 12-wk course of treatment based on the same manufacturing methods used in the large-scale generic production of HIV/AIDS medicines [12], and its findings have not been challenged.”
MethodBreakthroughs in hepatitis C research: from discovery to cure
Manns, M. P., & Maasoumy, B. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00608-8 · Cited by 231
APASL consensus statements and recommendation on treatment of hepatitis C
Omata, M., Kanda, T., Wei, L., Yu, M.-L., Chuang, W.-L., Ibrahim, A., Lesmana, C. R. A., Sollano, J., Kumar, M., Jindal, A., et al. (2016) · Hepatology International · doi:10.1007/s12072-016-9717-6 · Cited by 218
“However, the long duration of therapy (12–24 weeks) has raised concerns about adherence and cost [87].”
BackgroundPrevention of Hepatitis C by Screening and Treatment in U.S. Prisons
He, T., Li, K., Roberts, M. S., Spaulding, A. C., Ayer, T., Grefenstette, J. J., & Chhatwal, J. (2016) · Annals of Internal Medicine · doi:10.7326/m15-0617 · Cited by 167
“We assumed that in 2030, generic drugs would become available and that all patients would be eligible for treatment with low-cost drugs regardless of their fibrosis stage (28).”
BackgroundValue and affordability of CAR T-cell therapy in the United States
Fiorenza, S., Ritchie, D. S., Ramsey, S. D., Turtle, C. J., & Roth, J. A. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0956-8 · Cited by 166
“Although reductions in CAR T-cell manufacturing costs have been proposed as a means to decreasing price [69], in reality, the cost of pill manufacture for modern, high-cost therapies is pennies per gram [70].”
BackgroundHepatitis C virus treatment in the real world: optimising treatment and access to therapies
Zoulim, F., Liang, T. J., Gerbes, A. L., Aghemo, A., Deuffic‐Burban, S., Dusheiko, G. M., Fried, M. W., Pol, S., Rockstroh, J. K., Terrault, N. A., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-310421 · Cited by 158
Kohli, A., Osinusi, A., Sims, Z., Nelson, A., Meissner, E. G., Barrett, L. L., Bon, D., Marti, M. M., Silk, R., Kotb, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61228-9 · Cited by 150
Magri, A., Ozerov, A. A., Tunitskaya, V. L., Треворович, В.-Э. В., Wahid, A. M., Pirisi, M., Peter Simmonds, K., Ivanov, A. V., Novikov, M. S., & Patel, A. H. (2016) · Scientific Reports · doi:10.1038/srep31529 · Cited by 147
Nippes, R. P., Macruz, P. D., da Silva, G. N., & Scaliante, M. H. N. O. (2021) · Process Safety and Environmental Protection · doi:10.1016/j.psep.2021.06.040 · Cited by 124
Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study
Islam, N., Krajden, M., Shoveller, J., Gustafson, P., Gilbert, M., Buxton, J. A., Wong, J., TYNDALL, M. W., & Janjua, N. Z. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30182-0 · Cited by 116
“[4, 6-9] The high cost of direct-acting antivirals poses concomitant concerns regarding potential reinfection risks, and these concerns have fuelled debates regarding approaches to scaling-up treatment access[10, 11] especially amongst high-risk groups (e.”
BackgroundA path to eradication of hepatitis C in low- and middle-income countries
Graham, C. S., & Swan, T. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.004 · Cited by 115
Solomon, S. S., Mehta, S. H., Srikrishnan, A. K., Solomon, S., McFall, A. M., Laeyendecker, O. B., Celentano, D. D., Iqbal, H. S., Anand, S., Vasudevan, C. K., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71045-x · Cited by 105
Defining the concept of fair pricing for medicines
Moon, S., Mariat, S., Kamae, I., & Pedersen, H. B. (2020) · BMJ · doi:10.1136/bmj.l4726 · Cited by 104
Lau, G. K. K., Benhamou, Y., Chen, G., Li, J., Shao, Q., Ji, D., Li, F., Li, B., Liu, J., Hou, J., et al. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30015-2 · Cited by 103
Highly Divergent Hepaciviruses from African Cattle
Corman, V. M., Grundhoff, A. T., Baechlein, C., Fischer, N., Gmyl, A. P., Wollny, R., Dei, D., Ritz, D., Binger, T., Adankwah, E., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00393-15 · Cited by 98
“However, treatment options have improved recently by the availability of several direct-acting antivirals (5).”
BackgroundRapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
Hill, A. M., Simmons, B., Gotham, D., & Fortunak, J. (2016) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30691-9 · Cited by 98
“This analysis predicted 12-week course target prices of US$68–136 for sofosbuvir, and US$10–30 for daclatasvir [8].”
BackgroundSelf-citationWade, A., Doyle, J., Gane, E. J., Stedman, C. A. M., Draper, B. L., Iser, D. M., Roberts, S. K., Kemp, W. W., Petrie, D., Scott, N., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz546 · Cited by 98
“Worldwide, the availability of DAAs is variable due to their cost and patient- and provider-based restrictions [8, 9].”
BackgroundPisani, E., Nistor, A.-L., Hasnida, A., Parmaksiz, K., Xu, J., & Kok, M. O. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15236.1 · Cited by 95
Treating Hepatitis C in Lower-Income Countries
Jayasekera, C. R., Barry, M., Roberts, L. R., & Nguyen, M. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1400160 · Cited by 94
Minimum costs to manufacture new treatments for COVID-19
Hill, A. M., Wang, J., Levi, J., Heath, K., & Fortunak, J. (2020) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30018-2 · Cited by 93
“There are established methods for these calculations, which have reliably predicted the minimum costs of drugs to cure hepatitis c [22,23] and other diseases [24,25].”
Self-citationChallenges in managing HIV in people who use drugs
Kamarulzaman, A., & Altice, F. L. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000125 · Cited by 91
“Drug interactions and prohibitive costs of these new breakthroughs treatments, however, will restrict access to treatment for HIV PWUDs, especially in LMICs with limited resources and restricted ART options [89,90].”
BackgroundPathways to ensure universal and affordable access to hepatitis C treatment
Douglass, C. H., Pedrana, A. E., Lazarus, J. V., Hoen, E. ‘., Hammad, R., Baptista‐Leite, R., Hill, A. M., & Hellard, M. E. (2018) · BMC Medicine · doi:10.1186/s12916-018-1162-z · Cited by 84
Self-citationDisparity in market prices for hepatitis C virus direct-acting drugs
Andrieux-Meyer, I., Cohn, J., de Araújo, E. S. A., & Hamid, S. S. (2015) · The Lancet Global Health · doi:10.1016/s2214-109x(15)00156-4 · Cited by 83
Universal Medicine Access through Lump-Sum Remuneration — Australia’s Approach to Hepatitis C
Moon, S., & Erickson, E. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1813728 · Cited by 80
Trends in medicines procurement by the Brazilian federal government from 2006 to 2013
Luz, T. C. B., Osorio-de-Castro, C. G. S., Magarinos‐Torres, R., & Wettermark, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174616 · Cited by 79
Prevalence of major risk factors and use of screening tests for cancer in the United States
Fedewa, S. A., Sauer, A. G., Siegel, R. L., & Jemal, A. (2015) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0134 · Cited by 77
“However, there is some concern about the affordability and accessibility of these drugs, which may cost $64,000–84,000 for a course of treatment (96, 97).”
BackgroundTarget prices for mass production of tyrosine kinase inhibitors for global cancer treatment
Hill, A., Gotham, D., Fortunak, J., Meldrum, J., Erbacher, I., Martin, M., Shoman, H., Levi, J., Powderly, W. G., & Bower, M. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009586 · Cited by 68
“We derived target prices using an algorithm based on per-kilogram prices of the APIs, previously used in analyses of drugs for hepatitis C and B.(22) 23 Current manufacturers of API were contacted to request quotes for price per kilogram, and export data for India were”
MethodSelf-citationReview of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19
Pepperrell, T., Pilkington, V., Owen, A., Wang, J., & Hill, A. M. (2020) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30017-0 · Cited by 74
Self-citationLevi, J., Wang, J., Venter, F., & Hill, A. (2023) · Obesity · doi:10.1002/oby.23725 · Cited by 69
“generically [31]; however, this methodology is based on multiple assumptions.”
MethodSelf-citationHepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy
Lynch, S. M., & Wu, G. Y. (2016) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2016.00027 · Cited by 69
Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade
Barth, H. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i5.725 · Cited by 69
Current prices versus minimum costs of production for CFTR modulators
Guo, J., Wang, J., Zhang, J., Fortunak, J., & Hill, A. M. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.04.007 · Cited by 67
Self-citationAccess to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy
Trooskin, S. B., Reynolds, H., & Kostman, J. R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ677 · Cited by 67
“In India, Gilead was denied a patent [37], allowing that country’s generic sofosbuvir manufacturers to sell a 12-week course for <$250 [19].”
BackgroundDhiman, R. K., Grover, G. S., Premkumar, M., Taneja, S., Duseja, A. K., Arora, S., Rathi, S., Satsangi, S., & Roy, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.07.006 · Cited by 67
Capitalizing a Cure: How Finance Controls the Price and Value of Medicines
Roy, V. (2023) · University of California Press eBooks · doi:10.1525/9780520388727 · Cited by 66
Stasi, C., Silvestri, C., Voller, F., & Cipriani, F. (2015) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2015.05.004 · Cited by 66
Hepatitis C can be cured globally, but at what cost?
Hill, A., & Cooke, G. (2014) · Science · doi:10.1126/science.1257737 · Cited by 65
Self-citationRestrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics
Liao, J. M., & Fischer, M. A. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.303748 · Cited by 64
Photodegradation and ecotoxicology of acyclovir in water under UV254 and UV254/H2O2 processes
Russo, D., Siciliano, A., Guida, M., Galdiero, E., Amoresano, A., Andreozzi, R., Reis, N. M., Puma, G. L., & Marotta, R. (2017) · Water Research · doi:10.1016/j.watres.2017.06.020 · Cited by 64
Oxidative stress modulation in hepatitis C virus infected cells
Lozano-Sepúlveda, S. A., Bryan-Marrugo, O. L., Cordova-Fletes, C., Gutierrez-Ruiz, M. C., & Rivas-Estilla, A. M. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i29.2880 · Cited by 60
van de Ven, N., Fortunak, J., Simmons, B., Ford, N. P., Cooke, G., Khoo, S., & Hill, A. M. (2014) · Hepatology · doi:10.1002/hep.27641 · Cited by 58
“Previously published cost estimates for ribavirin, sofosbuvir, and daclatasvir5 were combined with those of the three new DAAs.”
BackgroundMethodInfluentialSelf-citationOptimising diagnosis of viraemic hepatitis C infection: the development of a target product profile
Reipold, E. I., Easterbrook, P., Trianni, A., Panneer, N., Krakower, D., Ongarello, S., Roberts, T., Miller, V., & Denkinger, C. M. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2770-5 · Cited by 58
“There has also been recent expansion of access in lowand middle income countries (LMIC) as a result of the availability of generic DAAs [5–7] resulting in substantial price reductions and price of US $ 100–250 for a 2-drug treatment course is within reach [8, 9].”
BackgroundRace, M., Ferraro, A., Galdiero, E., Guida, M., Núñez‐Delgado, A., Pirozzi, F., Siciliano, A., & Fabbricino, M. (2020) · Environmental Research · doi:10.1016/j.envres.2020.109808 · Cited by 57
“Moreover, further drawbacks are represented by AVs low biodegradability and their increasing use during pandemic outbreaks (Funke et al., 2016; Hill et al., 2014; Russo et al., 2017).”
Hoen, E. ‘., Boulet, P., & Baker, B. K. (2017) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-017-0107-9 · Cited by 55
Protease inhibitor therapy for hepatitis C virus-infection
de Leuw, P., & Stephan, C. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1454428 · Cited by 51
“A latterly published study estimated the cost of production of SOF to be US-$ 68–US-$ 136 for a 12-week course of treatment based on manufacturing methods used in the large-scale generic production of cART [101].”
MethodLentini, N. A., Foust, B. J., Hsiao, C. C., Wiemer, A. J., & Wiemer, D. F. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00655 · Cited by 50
Hill, A. M., Redd, C., Gotham, D., Erbacher, I., Meldrum, J., & Harada, R. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-011965 · Cited by 48
“previously used in analyses of drugs for hepatitis B, C, and oncology drugs.(13) 14 An example of our calculation algorithm for dasatinib is given in figure 1.”
BackgroundMethodSelf-citationMaistat, L., Кравченко, Н. Е., & Reddy, A. (2017) · Hepatology Medicine and Policy · doi:10.1186/s41124-017-0026-z · Cited by 48
Shortening the duration of therapy for chronic hepatitis C infection
Emmanuel, B., Wilson, E. M. P., OʼBrien, T. R., Kottilil, S., & Lau, G. K. K. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30053-5 · Cited by 48
Martin, N. K., Boerekamps, A., Hill, A. M., & Rijnders, B. J. A. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25062 · Cited by 48
“Promisingly, HCV DAA therapies could be produced as generics at a fraction of the current costs [64], particularly from within a country such as India due to its sizeable generic industry and low production costs.”
BackgroundSelf-citationDraper, B. L., Oo, Z. M., Thein, Z. W., Aung, P. P., Veronese, V., Ryan, C. E., Thant, M. M., Hughes, C., & Stoove, M. A. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.21885 · Cited by 46
Hepatitis C drug affordability
Kamal-Yanni, M. M. (2015) · The Lancet Global Health · doi:10.1016/s2214-109x(14)70365-1 · Cited by 45
Hézode, C. (2016) · Journal of Viral Hepatitis · doi:10.1111/jvh.12635 · Cited by 43
Zimmermann, R., Kollan, C., Ingiliz, P., Mauss, S., Schmidt, D., & Bremer, V. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.024 · Cited by 41
“A recently published paper estimated the costs of production of SOF to be tremendously lower than the market price [41].”
BackgroundCan hepatitis C be eradicated in the United States?
Edlin, B. R., & Winkelstein, E. R. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.07.015 · Cited by 41
“The drugs are inexpensive to produce (Hill et al., 2014) and it would be irresponsible to let the epidemic continue to spread while they sit on the shelf.”
BackgroundFord, N. P., Swan, T., Beyer, P., Hirnschall, G. O., Easterbrook, P., & Wiktor, S. Z. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.09.019 · Cited by 39
Self-citation‘Government Patent Use’: A Legal Approach To Reducing Drug Spending
Kapczynski, A., & Kesselheim, A. S. (2016) · Health Affairs · doi:10.1377/hlthaff.2015.1120 · Cited by 39
Pharmaceutical Capitalism and its Logistics: Access to Hepatitis C Treatment
Quet, M. (2017) · Theory Culture & Society · doi:10.1177/0263276417727058 · Cited by 38
“estimated the cost of manufacturing for a 12-week treatment of sofosbuvir to be between $68 and $136 (Hill et al., 2014).”
BackgroundLenacapavir to prevent HIV infection: current prices versus estimated costs of production
Hill, A. M., Levi, J., Fairhead, C., Pilkington, V., Wang, J., Johnson, M., Layne, J., Roberts, D. N., & Fortunak, J. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae305 · Cited by 38
Self-citationHill, A. M., Gotham, D., Cooke, G., Bhagani, S., Andrieux‐Meyer, I., Cohn, J., & Fortunak, J. (2015) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30484-2 · Cited by 38
Self-citationHellard, M. E., Sacks‐Davis, R., & Doyle, J. (2016) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2015-205454 · Cited by 39
Echevarria, D., Gutfraind, A., Boodram, B., Major, M. E., Valle, S. Y. D., Cotler, S. J., & Dahari, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135901 · Cited by 37
“[43] projected that, within the next 15 years, large-scale manufacture of DAAs could reduce the manufacturing cost for a 12 week course to as low as $100–$250 per person.”
Access to hepatitis C medicines
Edwards, D., Coppens, D., Prasad, T. L., Rook, L. A., & Iyer, J. K. (2015) · Bulletin of the World Health Organization · doi:10.2471/blt.15.157784 · Cited by 37
Azbel, L., Wickersham, J. A., Wegman, M. P., Polonsky, M., Suleymanov, M., Ismayilov, R., Дворяк, С., Rotberga, S., & Altice, F. L. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.02.034 · Cited by 36
“Evidence of significantly reduced pricing is emerging, however, including availability of generic medications (Hill et al., 2014).”
BackgroundZahnd, C., Vizcaya, L. S., Dufour, J., Müllhaupt, B., Wandeler, G., Kouyos, R. D., Estill, J. A. M., Bertisch, B., Rauch, A., & Keiser, O. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.030 · Cited by 36
“Yet the very high cost of the DAAs represents a major barrier to widespread treatment scale-up and is a matter of debate [25].”
BackgroundMesquita, F., Santos, M. É., Benzaken, A. S., Corrêa, R. G., Catapan, E., Sereno, L. S., & Naveira, M. C. M. (2016) · BMC Public Health · doi:10.1186/s12889-016-3784-4 · Cited by 36
“The global scientific community and civil society have objected to the financial restrictions imposed on the right to health [8].”
BackgroundMagrì, A., Reilly, R., Scalacci, N., Radi, M., Hunter, M., Ripoll, M., Patel, A. H., & Castagnolo, D. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.09.029 · Cited by 36
Flexner, C. W., Thomas, D. L., & Swindells, S. (2018) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000510 · Cited by 35
Estimated generic prices for novel treatments for drug-resistant tuberculosis
Gotham, D., Fortunak, J., Pozniak, A., Khoo, S., Cooke, G., Nytko, F. E., & Hill, A. M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw522 · Cited by 35
Self-citationIntroduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future
de Bruijn, W., Ibáñez-Lorente, C., Frisk, P., Pedersen, H. B., Alkan, A., Bonanno, P. V., Brkičić, L. S., Bucsics, A., Dedet, G., Eriksen, J., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00197 · Cited by 34
“…prices of second generation DAAs will continue falling across countries with estimates of manufacturing for 12-week courses at US$10-$30 for daclatasvir, US$68–$136 for sofosbuvir, US$100–$210 for faldaprevir and US$130–$270 for simeprevir (Hill et al., 2014) coupled with increased competition.”
BackgroundFord, N. P., Wiktor, S. Z., Kaplan, K., Andrieux‐Meyer, I., Hill, A. M., Radhakrishnan, P., Londeix, P., Forette, C., Momenghalibaf, A., Verster, A. D., et al. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.05.004 · Cited by 32
Self-citationBognar, C. L. F. B., Bychkovsky, B., & Lopes, G. D. L., Jr. (2016) · Journal of Global Oncology · doi:10.1200/jgo.2016.005363 · Cited by 32
“For example, a typical 12-week course of sofosbuvir is US$84,000 per patient, although total production costs are only US$68 to US$136.(22,23) To circumvent the high cost, efforts in many LMICs”
BackgroundInfluentialFuture of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?
Dhiman, R. K. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2014.06.011 · Cited by 31
The use of generic medications for hepatitis C
Freeman, J. A., & Hill, A. M. (2016) · Liver International · doi:10.1111/liv.13157 · Cited by 31
“Although the ingredients for a 12-week course of Sovaldi cost less than $100 (13), the US retail price is a staggering $84 000 (Fig.”
BackgroundSelf-citationGoing Viral: An Investigation into the Chameleonic Behaviour of Antiviral Compounds
Wieske, L. H. E., Atilaw, Y., Poongavanam, V., Erdélyi, M., & Kihlberg, J. O. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202202798 · Cited by 31
Equitable and Effective Distribution of the COVID-19 Vaccines – A Scientific and Moral Obligation
Binagwaho, A., Mathewos, K., & Davis, S. (2021) · International Journal of Health Policy and Management · doi:10.34172/ijhpm.2021.49 · Cited by 31
Real-world challenges for hepatitis C virus medications: a critical overview
Shahid, I., Almalki, W. H., Hassan, S., & Hafeez, M. H. (2017) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2017.1329277 · Cited by 29
“Generic versions of sofosbuvir (an NS5B inhibitor), ledipasvir, and daclatasvir (NS5A inhibitors) are mass produced for 1% of the current retail price in the US, but unfortunately, these life-saving medications are not being deployed on a mass scale (Hill et al. 2014; Freeman et al. 2016).”
BackgroundMethodResultInfluentialHepatitis C: Treatment of difficult to treat patients
Hilgenfeldt, E., Schlachterman, A., & Firpi, R. J. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i15.1953 · Cited by 28
Liu, C., Sun, H., Liu, C., Sheng, W., Hsieh, S., Lo, Y., Liu, W., Su, T., Yang, H., Hong, C., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14647 · Cited by 27
“However, the significantly lower prices of generic DAAs are still appealing to many patients who have limited access to the brand-name agents.(34-36) In Taiwan, the National Health Insurance reimbursed DCV plus asunaprevir (ASV), PrOD or EBR plus GZR only for HCV-1 patients with advanced hepatic fibrosis or compensate…”
BackgroundCompras públicas de medicamentos para hepatite C no Brasil no período de 2005 a 2015
Chaves, G. C., Osorio-de-Castro, C. G. S., & Oliveira, M. A. (2017) · Ciência & Saúde Coletiva · doi:10.1590/1413-81232017228.05602017 · Cited by 27
Hassab, M. A. E., El-Bastawissy, E. A., & El-Moselhy, T. F. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1332689 · Cited by 27
Hepatitis C Treatment: Clinical Issues for Psychiatrists in the Post-Interferon Era
Chasser, Y., Kim, A. Y., & Freudenreich, O. (2016) · Psychosomatics · doi:10.1016/j.psym.2016.09.004 · Cited by 26
Towards hepatitis C eradication from the HIV-infected population
Barreiro, P., Fernández-Montero, J. V., de Mendoza, C., Labarga, P., & Soriano, V. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.02.004 · Cited by 25
Tell Me How It Ends: The Path to Nationalizing the U.S. Pharmaceutical Industry
Quigley, F. (2019) · University of Michigan Journal of Law Reform · doi:10.36646/mjlr.53.4.tell · Cited by 25
Who is more likely to hesitate to accept COVID-19 vaccine: a cross-sectional survey in China
Zhang, P., Zhang, Q., Guan, H., Fan, K., Bi, X., Huang, Y., Liang, L., Khoso, A. R., Xu, X., Ma, Y., et al. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2019581 · Cited by 25
“Price and affordability of the vaccine are the key points of affordability [72].”
BackgroundAkiyama, M. J., Muller, A., Huang, O., Lizcano, J. A., Nyakowa, M., Riback, L. R., Ross, J., Bundi, H., Kulabi, E. S., Mwangi, A. M., et al. (2021) · Global Public Health · doi:10.1080/17441692.2021.1896763 · Cited by 24
“While it is anticipated that resources will become more widely available (Graham & Swan, 2015; Hill et al., 2014), data are limited on how to effectively deliver community-level HCV care in LMICs (Morgan et al.”
BackgroundInfluentialInterferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients
Haj-Sheykholeslami, A., Keshvari, M., Sharafi, H., Pouryasin, A., Hemmati, K., & Mohammadzadehparjikolaei, F. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i29.8935 · Cited by 24
New drug pricing: does it make any sense?
Gagnon, M. (2015) · PubMed · Cited by 22
Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace
Clercq, E. D. (2015) · Reviews in Medical Virology · doi:10.1002/rmv.1842 · Cited by 21
“This would make the large-scale manufacture of two-drug to three-drug combinations of HCV DAAs a feasible goal with a minimum target price of $100–250 per 12-week treatment course [147].”
BackgroundThe High Price of the New Hepatitis C Virus Drugs
Steinbrook, R., & Redberg, R. F. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2135 · Cited by 21
Global policy and access to new hepatitis C therapies for people who inject drugs
Doyle, J., Aspinall, E., Hutchinson, S. J., Quinn, B., Gore, C., Wiktor, S. Z., & Hellard, M. E. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.05.008 · Cited by 20
“sofosbuvir could cost as much as US$1000 per pill or US$84,000 for a 12 week course of treatment [49].”
BackgroundChabrol, F., David, P., & Krikorian, G. (2017) · Social Science & Medicine · doi:10.1016/j.socscimed.2017.03.059 · Cited by 20
Five Questions Concerning Managing Hepatitis C in the Justice System
Spaulding, A. C., Adee, M. G., Lawrence, R., Chhatwal, J., & von Oehsen, W. H. (2018) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2018.02.014 · Cited by 20
Matthews, D. W., Coleman, S., Razavi, H. A., & Izaret, J.-M. (2022) · Liver International · doi:10.1111/liv.15245 · Cited by 20
Fichter, M., Piradashvili, K., Pietrzak-Nguyen, A., Pretsch, L., Kuhn, G., Strand, S., Knuf, M., Zepp, F., Wurm, F. R., Mailänder, V., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.046 · Cited by 20
Ali, H., Vikash, F., Moond, V., Khalid, F., Jamil, A. R., Dahiya, D. S., Sohail, A. H., Gangwani, M. K., Patel, P., & Satapathy, S. K. (2024) · World Journal of Virology · doi:10.5501/wjv.v13.i1.89469 · Cited by 19
Potential market size and impact of hepatitis C treatment in low‐ and middle‐income countries
Woode, M. E., Abu‐Zaineh, M., Perriëns, J. H., Renaud, F., Wiktor, S. Z., & Moatti, J. (2016) · Journal of Viral Hepatitis · doi:10.1111/jvh.12516 · Cited by 19
All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality
Adinolfi, L. E., & Guerrera, B. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i22.2363 · Cited by 18
Metadata
- Authors
- Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N.
- Affiliations
- University of Liverpool (GB)
- Howard University (US)
- Imperial College London (GB)
- University of Cape Town (ZA)
- Corresponding author
- Hill, A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-06
- Volume
- 58
- Issue
- 7
- Pages
- 928-936
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC3952605
- OpenAlex
- W2163848297
- Semantic Scholar
- 777a83aedceb6c84d3ff7d4176d38d6c2613d4a5
- Cited by
- 216
- References
- 28
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 8 · 2023: 10 · 2022: 9 · 2021: 5 · 2020: 15 · 2019: 14 · 2018: 22 · 2017: 26 · 2016: 34 · 2015: 43 · 2014: 24
- FWCI
- 23.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Clinical Infectious Diseases (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- hepatitis C, direct-acting antivirals, cost projections, daclatasvir, sofosbuvir, simeprevir, faldaprevir, ribavirin, generic drug production, treatment access, low- and middle-income countries, drug pricing
- MeSH terms
- Sofosbuvir, Simeprevir, Aminoisobutyric Acids, Antiviral Agents, Carbamates, Developing Countries, Drug Industry, Drug Therapy, Combination, Health Services Accessibility, Hepatitis C, Heterocyclic Compounds, 3-Ring, Humans, Imidazoles, Leucine, Oligopeptides, Proline, Pyrrolidines, Quinolines, Ribavirin, Sulfonamides, Thiazoles, Uridine Monophosphate, Valine, Hepacivirus, Anti-HIV Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.